Harmony Biosciences (HRMY)
(Delayed Data from NSDQ)
$34.40 USD
-0.78 (-2.22%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $34.38 -0.02 (-0.06%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth A Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Harmony Biosciences Holdings, Inc. has a PEG ratio of 0.58 compared to the Medical - Biomedical and Genetics industry's PEG ratio of 1.85.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
HRMY 34.40 -0.78(-2.22%)
Will HRMY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for HRMY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HRMY
Analysts Estimate Stoke Therapeutics, Inc. (STOK) to Report a Decline in Earnings: What to Look Out for
Harmony Biosciences Holdings, Inc. (HRMY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
HRMY: What are Zacks experts saying now?
Zacks Private Portfolio Services
REGN Q2 Earnings: Will Higher Dupixent Profits Fuel Growth?
Tenet Beats Q2 Earnings on Strong Patient Volumes, Hikes '25 EPS View
5 High Earnings Yield Stocks to Tap Into Value Investing Gains
Other News for HRMY
Harmony Biosciences Holdings Inc (HRMY) to Announce Q2 2025 Financial Results | HRMY stock news
Harmony Biosciences to Report Second Quarter 2025 Financial Results on August 5, 2025 | HRMY ...
Truist Securities Initiates Coverage on Harmony Biosciences (HRMY) with Buy Rating | HRMY Stock News
Truist Initiates Buy Rating for Harmony Biosciences (HRMY) with Promising Growth Prospects | ...
Harmony Biosciences initiated with bullish view at Truist, here's why